THE 2-MINUTE RULE FOR IS ABBV-744 EFFECTIVE FOR HEMATOLOGIC CANCERS?

In Section C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment until disorder progression or the members are unable to tolerate the study drugs.For all move cytometry experiments, 10,000 cells for every replicate have been analyzed, and three replicates